US Stock MarketDetailed Quotes

NVO Novo-Nordisk A/S

Watchlist
  • 85.000
  • -18.440-17.83%
Close Dec 20 16:00 ET
  • 86.090
  • +1.090+1.28%
Post 20:01 ET
378.77BMarket Cap28.86P/E (TTM)

Novo-Nordisk A/S Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Novo-Nordisk A/S Q3 2024 Earnings Date

Currency：DKKNov 6, 2024

Estimate
(YoY)		 Actual
(YoY)		 Vs Estimate
(% Chg)
Revenue
71.87B
71.31B
-558.36M
Miss Est.
+22.37%
+21.42%
-0.78%
EPS
5.95
6.12
+0.17
Beat Est.
+19.03%
+22.40%
+2.83%
Analyst Rating
Buy

Dec 20, 2024

Novo-Nordisk A/S Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 2 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: DKK

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 79.538B--
--2024/Q4-- / 81.107B--
Nov 6, 20242024/Q371.311B / 71.869B--
Aug 7, 20242024/Q268.060B / 68.563B--
May 2, 20242024/Q165.349B / 63.573B--
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 79.538B--
--2024/Q4-- / 81.107B--
Nov 6, 20242024/Q371.311B / 71.869B--
Aug 7, 20242024/Q268.060B / 68.563B--
May 2, 20242024/Q165.349B / 63.573B--

Unlock Free Earnings Estimates

Novo-Nordisk A/S Earnings Reports

  • 6-K: Financial Report for the Period 1 January 2024 to 30 September 2024

    Nov 6 06:37 ET

  • 6-K: Financial Report for the Period 1 January 2024 to 30 June 2024

    Aug 7 06:56 ET

  • 6-K: Novo Nordisk Stops the Ocedurenone CLARION-CKD Trial and Recognises Impairment Loss

    Jun 26 13:22 ET

  • 6-K: Financial Report for the Period 1 January 2024 to 31 March 2024

    May 2 07:18 ET

    • Read more

    Analysis

    Analyst Rating

    Updated: Dec 20, 2024

    Buy

    • Buy

      57.14%

    • Hold

      28.57%

    • Sell

      14.29%

    Price Target

    No Data

    Heat List
    US
    Overall
    Symbol
    Price
    % Chg

    No Data

    Investment Theme Weight Loss Drugs
    Weight Loss Drugs
    Intraday-4.61%